SEC Filing Summary
Entity mismatch: The supplied filing is StemCells, Inc.’s Form 10-Q, not a filing for Microbot Medical Inc. This summary covers StemCells’ quarter ended March 31, 2012.
Business context and reporting period
StemCells is a biopharmaceutical company developing stem-cell therapeutics and related research products. Its principal clinical programs used HuCNS-SC cells for Pelizaeus-Merzbacher disease (PMD), chronic spinal cord injury and dry age-related macular degeneration (AMD). The financial statements are unaudited and compare the three months ended March 31, 2012 with the same period in 2011.
Key financial metrics
| Metric | Q1 2012 | Q1 2011 or prior balance-sheet date |
|---|---|---|
| Revenue | $644,036 | $221,467 |
| Gross profit / gross margin | $572,077 / approximately 88.8% | $166,943 / approximately 75.4% |
| Research and development expense | $3,938,391 | $5,525,677 |
| Selling, general and administrative expense | $1,924,325 | $2,075,729 |
| Operating loss | $(5,325,794) | $(7,509,600) |
| Net loss | $(10,229,439) | $(5,747,235) |
| Basic and diluted loss per share | $(0.45) | $(0.42) |
| Cash used in operating activities | $(5,630,679) | $(7,418,330) |
| Cash and cash equivalents at quarter-end | $9,454,753 | $13,311,261 at Dec. 31, 2011 |
| Cash, equivalents and current marketable securities | $11,602,452 | $16,591,852 at Dec. 31, 2011 |
| Current assets / current liabilities | $12,336,580 / $4,547,144 | $17,388,406 / $5,653,254 at Dec. 31, 2011 |
| Bonds payable | $476,250 total | $522,500 at Dec. 31, 2011 |
Material changes versus prior comparable period
- Revenue increased 191%, reflecting an 82% rise in product sales, primarily higher volume in SC Proven media and reagents, and higher licensing and grant revenue, primarily from the genOway IRES license.
- Operating expenses fell 23%. R&D expense declined 29%, with the company citing lower personnel and facility costs, consolidated U.K. operations and reduced clinical and external-service costs.
- Despite the smaller operating loss, net loss widened. A $4.94 million warrant-liability remeasurement loss in Q1 2012 compared with $1.78 million of warrant-liability remeasurement income in Q1 2011 was the principal difference.
- Operating cash use improved by approximately $1.79 million year over year. Cash and cash equivalents declined by approximately $3.86 million from year-end; the company also reported net cash proceeds from investing activities, principally reflecting marketable-security maturities.
- Stockholders’ equity fell to $2.01 million from $10.73 million at year-end, while the recorded warrant liability rose to $11.02 million from $6.04 million.
Outlook, commentary, risks and unusual items
- Management said it expects additional operating losses and does not expect profitability in the next several years. It stated that significant additional capital is needed to fund development and operations, and warned that insufficient financing could force delays, reductions or elimination of programs and could impair its ability to meet obligations.
- At March 31, cash, cash equivalents and current marketable securities totaled approximately $11.60 million. The company reported approximately $46 million remaining under its $100 million shelf registration statement as of April 30, 2012; availability does not assure financing on acceptable terms.
- The company completed its four-patient Phase I PMD trial in February 2012. Reported results were preliminary: evidence of donor-derived myelination was described in all four patients, with measurable neurological and/or motor gains in three and clinical stability in one. Additional trials are needed to establish safety and efficacy.
- The FDA authorized a Phase I/II dry AMD trial in January 2012; the company expected to initiate it later in 2012. Its Swiss Phase I/II chronic spinal cord injury trial had enrolled and dosed its first cohort by December 2011.
- Warrant accounting materially affected reported earnings: warrants were classified as liabilities and remeasured using valuation models, including Level 3 assumptions. The company reported 17.43 million outstanding warrants at March 31, 2012, with a fair-value liability of $11.02 million.
- After quarter-end, additional Series B warrant exercises generated $2.25 million gross proceeds in April and May. Of the 8 million Series B warrants issued in the December 2011 financing, 2.7 million were exercised in total and the remainder expired by May 2, 2012. The filing cover reports 25,329,246 common shares issued and outstanding at May 8, compared with 23,444,881 at March 31.
- Contractual cash obligations totaled $19.55 million, including $18.99 million of operating lease payments. The Newark headquarters and research-space lease has an approximately 11.5-year initial term and approximately $17.87 million of aggregate rent. The Rhode Island facility lease expires June 30, 2013; the company estimated 2012 net cash outlay there at approximately $1.43 million.
- Neuralstem patent litigation remained ongoing, with discovery in progress and a trial anticipated in 2013. Neuralstem had appealed a European Patent Office decision invalidating its patent’s composition claims.
Most important facts for investors to verify
- Confirm the issuer identity: this filing is for StemCells, Inc., not Microbot Medical Inc.
- Review financing needs and cash burn against the company’s statement that it requires significant additional capital; the filing does not provide a specific cash-runway estimate.
- Assess the clinical evidence and regulatory status of the PMD, spinal cord injury and AMD programs, including the preliminary nature of PMD results.
- Check warrant terms, post-quarter exercises and resulting share-count changes, as well as the effect of warrant remeasurement on reported earnings and potential dilution.
- Evaluate lease commitments, Rhode Island wind-down assumptions and the status and potential costs or outcomes of the Neuralstem litigation.